IMPEDIMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.093 AUD | -2.11% |
|
+1.09% | -35.86% |
| Apr. 17 | Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant | MT |
| Apr. 17 | Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Companyâs SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.095
AUD
Average target price
0.176
AUD
Spread / Average Target
+85.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.86% | 124M | |
| +2.02% | 207B | |
| +2.17% | 175B | |
| +10.45% | 132B | |
| +16.62% | 99.1B | |
| -3.80% | 60.89B | |
| +13.38% | 52.04B | |
| -6.33% | 45.48B | |
| -4.74% | 38.81B | |
| +9.89% | 38.77B |
- Stock Market
- Equities
- IPD Stock
- News ImpediMed Limited
- ImpediMed : SOZO Devices Selected by AstroZeneca for Renal Trial; Shares Climb 12%
